Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Purchased by Fmr LLC

Fmr LLC raised its stake in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) by 27.1% during the third quarter, HoldingsChannel reports. The fund owned 118,265 shares of the biopharmaceutical company’s stock after acquiring an additional 25,183 shares during the quarter. Fmr LLC’s holdings in Puma Biotechnology were worth $302,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new stake in shares of Puma Biotechnology in the 3rd quarter valued at about $34,000. Victory Capital Management Inc. bought a new stake in Puma Biotechnology in the second quarter valued at about $54,000. Dynamic Technology Lab Private Ltd acquired a new stake in Puma Biotechnology during the third quarter valued at approximately $44,000. The Manufacturers Life Insurance Company acquired a new stake in Puma Biotechnology during the second quarter valued at approximately $58,000. Finally, Patriot Financial Group Insurance Agency LLC lifted its holdings in Puma Biotechnology by 72.7% during the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 19,000 shares of the biopharmaceutical company’s stock worth $48,000 after buying an additional 8,000 shares during the last quarter. 61.29% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PBYI has been the subject of a number of research analyst reports. StockNews.com downgraded Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Friday, December 6th. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Puma Biotechnology in a report on Wednesday, November 20th.

Puma Biotechnology Price Performance

Shares of NASDAQ:PBYI opened at $2.75 on Friday. The company has a market cap of $134.99 million, a PE ratio of 5.73 and a beta of 1.08. Puma Biotechnology, Inc. has a fifty-two week low of $2.22 and a fifty-two week high of $7.73. The firm has a 50-day simple moving average of $2.95 and a 200 day simple moving average of $3.00. The company has a quick ratio of 1.40, a current ratio of 1.42 and a debt-to-equity ratio of 0.46.

Puma Biotechnology (NASDAQ:PBYI) last issued its earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, beating analysts’ consensus estimates of $0.31 by $0.10. The company had revenue of $80.50 million during the quarter, compared to the consensus estimate of $71.32 million. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. During the same period in the previous year, the firm posted $0.12 earnings per share. On average, sell-side analysts anticipate that Puma Biotechnology, Inc. will post 0.31 EPS for the current year.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.